← Leaderboards
Seema Ahsan Khan
Northwestern University
$17,558,735
Attributed
$19,277,334
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,277,334 · 9
By mechanism
UG1$10,024,720 · 1
R01$6,417,420 · 3
T32$1,275,247 · 1
R38$1,002,003 · 1
P30$484,444 · 2
R03$73,500 · 1
Top collaborators
- Ji-Yong Julie Kim5 shared
- Ronald T. Ackermann3 shared
- Karl Y Bilimoria3 shared
Most similar at Northwestern University
Same institution · by research overlap
- Vadim Backman$34,873,053
- Serdar E Bulun$27,655,930
- Hariharan Subramanian$1,672,189
- Vadim Backman$5,238,271
- Chad A. Mirkin$20,335,625
Others in their field
Top investigators on “Prevention”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventionMalignant NeoplasmsMalignant Breast NeoplasmSuccessProgramsResearch PersonnelDesignAreaCancer PreventionBiological MarkersPharmaceutical PreparationsComprehensive Cancer CenterCollaborationsPathway InteractionsBreast Cancer PreventionBreastCancer RiskFundingEnvironmentPreventFosteringInnovationGenetic Predisposition To DiseaseIncidence
Grant awards (43)
Northwestern Cancer Prevention Consortium$1,870,000
UG1 · FY2025 · CA · contact PI
Cancer Prevention$82,341
P30 · FY2025 · CA · contact PI
Northwestern Cancer Prevention Consortium$983,603
UG1 · FY2024 · CA · contact PI
COllaborative Northwestern Surgical Oncology Research Training (CONSORT)$351,352
T32 · FY2024 · CA · contact PI
Surgical Multispecialty Access to Research in Residency Training (SMART)$248,302
R38 · FY2024 · CA · contact PI
Cancer Prevention (CP) Research Program$52,781
P30 · FY2024 · CA · contact PI
Northwestern Cancer Prevention Consortium$1,935,399
UG1 · FY2023 · CA · contact PI
Determinants of transdermal drug delivery to the normal and the radiated breast$593,407
R01 · FY2023 · CA · contact PI
Surgical Multispecialty Access to Research in Residency Training (SMART)$251,502
R38 · FY2023 · CA · contact PI
COllaborative Northwestern Surgical Oncology Research Training (CONSORT)$156,805
T32 · FY2023 · CA · contact PI
Cancer Prevention (CP) Research Program$52,781
P30 · FY2023 · CA · contact PI
Determinants of transdermal drug delivery to the normal and the radiated breast$354,475
R01 · FY2022 · CA · contact PI
Northwestern Cancer Prevention Consortium$298,222
UG1 · FY2022 · CA · contact PI
Surgical Multispecialty Access to Research in Residency Training (SMART)$251,502
R38 · FY2022 · CA · contact PI
COllaborative Northwestern Surgical Oncology Research Training (CONSORT)$144,883
T32 · FY2022 · CA · contact PI
Cancer Prevention (CP) Research Program$54,292
P30 · FY2022 · CA · contact PI
Northwestern Cancer Prevention Consortium$1,974,998
UG1 · FY2021 · CA · contact PI
Determinants of transdermal drug delivery to the normal and the radiated breast$361,703
R01 · FY2021 · CA · contact PI
COllaborative Northwestern Surgical Oncology Research Training (CONSORT)$308,857
T32 · FY2021 · CA
Surgical Multispecialty Access to Research in Residency Training (SMART)$250,697
R38 · FY2021 · CA
Cancer Prevention (CP) Research Program$54,292
P30 · FY2021 · CA · contact PI
Northwestern Cancer Prevention Consortium$1,974,998
UG1 · FY2020 · CA · contact PI
Determinants of transdermal drug delivery to the normal and the radiated breast$363,218
R01 · FY2020 · CA · contact PI
COllaborative Northwestern Surgical Oncology Research Training (CONSORT)$313,350
T32 · FY2020 · CA
Cancer Prevention (CP) Research Program$54,292
P30 · FY2020 · CA · contact PI
Northwestern Cancer Prevention Consortium$987,500
UG1 · FY2019 · CA · contact PI
Determinants of transdermal drug delivery to the normal and the radiated breast$374,669
R01 · FY2019 · CA · contact PI
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention$348,917
R01 · FY2019 · CA · contact PI
Cancer Prevention (CP) Research Program$54,292
P30 · FY2019 · CA · contact PI
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention$377,020
R01 · FY2018 · CA · contact PI
Cancer Prevention (CP) Research Program$55,369
P30 · FY2018 · CA · contact PI
Cancer Prevention (CP) Research Program$8,620
P30 · FY2018 · CA · contact PI
Cancer Prevention (CP) Research Program$8,488
P30 · FY2018 · CA · contact PI
Cancer Prevention (CP) Research Program$6,896
P30 · FY2018 · CA · contact PI
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention$396,152
R01 · FY2017 · CA · contact PI
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention$410,295
R01 · FY2016 · CA · contact PI
Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention$378,871
R01 · FY2015 · CA · contact PI
Nipple Fluid Hormone Levels and Breast Cancer Risk$454,396
R01 · FY2011 · CA · contact PI
Nipple Fluid Hormone Levels and Breast Cancer Risk$510,273
R01 · FY2010 · CA · contact PI
Nipple Fluid Hormone Levels and Breast Cancer Risk$504,710
R01 · FY2009 · CA · contact PI
Nipple Fluid Hormone Levels and Breast Cancer Risk$494,452
R01 · FY2008 · CA · contact PI
Nipple Fluid Hormone Levels and Breast Cancer Risk$494,862
R01 · FY2007 · CA · contact PI
NORMAL BREAST ESTROGEN RESPONSE &BREAST CANCER ETIOLOGY$73,500
R03 · FY2000 · CA